Citadel Advisors
CLDI icon

Citadel Advisors’s Calidi Biotherapeutics CLDI Stock Holding History

Citadel Advisors’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-371
Closed -$16.4K – 12892
2025
Q2 		$16.4K Buy
+371
New +$28.8K ﹤0.01% 12145
2024
Q3 		– Sell
-66
Closed -$25.2K – 14320
2024
Q2 		$25.2K Buy
+66
New +$33.7K ﹤0.01% 12430
2023
Q1 		– Sell
-49
Closed -$954K – 14797
2022
Q4 		$954K Hold
49
– – ﹤0.01% 6909
2022
Q3 		$924K Buy
+49
New +$940K ﹤0.01% 7173

Other funds holding CLDI

HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $517M AUM 16.68% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
AMH
Apollo Management Holdings New York $7.6B AUM 23.97% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return

Citadel Advisors's CLDI Position: Q3 2025 in Review

Citadel Advisors sold out of Calidi Biotherapeutics (CLDI) in Q3 2025, closing a stake of 371 shares — an estimated $16.4K sold.

Citadel Advisors first reported a position in CLDI in Q3 2022 and held it in 4 quarters. The position peaked at $954K in Q4 2022. 21 funds tracked by Wall St. Rank hold CLDI as of Q3 2025.

  • Citadel Advisors reported no remaining Calidi Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Citadel Advisors sold 371 Calidi Biotherapeutics shares in Q3 2025, an estimated $16.4K.
  • Citadel Advisors first reported a position in Calidi Biotherapeutics in Q3 2022 and held it in 4 quarters.
  • Citadel Advisors's Calidi Biotherapeutics position peaked at $954K in Q4 2022.
  • 21 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.